Laurence H Hurley

List of Publications by Year
in descending order

183	22,555	10373 72	8384 147
papers	citations	h-index	g-index

186	186	186	11400
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The role of G-Quadruplex DNA in Paraspeckle formation in cancer. Biochimie, 2021, 190, 124-131.	1.3	10
2	Scavenging of Labile Heme by Hemopexin Is a Key Checkpoint in Cancer Growth and Metastases. Cell Reports, 2020, 32, 108181.	2.9	27
3	DNA G-Quadruplex and i-Motif Structure Formation Is Interdependent in Human Cells. Journal of the American Chemical Society, 2020, 142, 20600-20604.	6.6	74
4	Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex. Oncotarget, 2020, 11, 1758-1776.	0.8	7
5	TGFâ€Î²â€induced fibrotic stress increases Gâ€quadruplex formation in human fibroblasts. FEBS Letters, 2019, 593, 3149-3161.	1.3	8
6	Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death. Cell Chemical Biology, 2019, 26, 1110-1121.e4.	2.5	41
7	In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells. BMC Cancer, 2019, 19, 1251.	1.1	19
8	Specific G-quadruplex ligands modulate the alternative splicing of Bcl-X. Nucleic Acids Research, 2018, 46, 886-896.	6.5	64
9	The 3â€²-end region of the human PDGFR-Î² core promoter nuclease hypersensitive element forms a mixture of two unique end-insertion G-quadruplexes. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 846-854.	1.1	15
10	Intracellular speciation of gold nanorods alters the conformational dynamics of genomic DNA. Nature Nanotechnology, 2018, 13, 1148-1153.	15.6	16
11	HMGB1 binds to the KRAS promoter G-quadruplex: a new player in oncogene transcriptional regulation?. Chemical Communications, 2018, 54, 9442-9445.	2.2	46
12	The Consequences of Overlapping G-Quadruplexes and i-Motifs in the Platelet-Derived Growth Factor Receptor Î² Core Promoter Nuclease Hypersensitive Element Can Explain the Unexpected Effects of Mutations and Provide Opportunities for Selective Targeting of Both Structures by Small Molecules To Downregulate Gene Expression. Journal of the American Chemical Society, 2017, 139, 7456-7475.	6.6	77
13	Insight into the Complexity of the i-Motif and G-Quadruplex DNA Structures Formed in the KRAS Promoter and Subsequent Drug-Induced Gene Repression. Journal of the American Chemical Society, 2017, 139, 8522-8536.	6.6	140
14	Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. Journal of Medicinal Chemistry, 2017, 60, 6587-6597.	2.9	30
15	Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Research, 2017, 27, 524-532.	2.4	122
16	Identification of G-quadruplexes in long functional RNAs using 7-deazaguanine RNA. Nature Chemical Biology, 2017, 13, 18-20.	3.9	59
17	A Mechanosensor Mechanism Controls the G-Quadruplex/i-Motif Molecular Switch in the MYC Promoter NHE III₁. Journal of the American Chemical Society, 2016, 138, 14138-14151.	6.6	96
18	Interaction of Individual Structural Domains of hnRNP LL with the BCL2 Promoter i-Motif DNA. Journal of the American Chemical Society, 2016, 138, 10950-10962.	6.6	40

#	Article	IF	Citations
19	A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters. Journal of the American Chemical Society, 2016, 138, 13673-13692.	6.6	91
20	Concurrent Targeting of BCL2 and MYC Transcription Leads to Chemo-Sensitization of Dual-Expressing Diffuse Large B-Cell Lymphoma In Vivo. Blood, 2016, 128, 4090-4090.	0.6	0
21	Molecular population dynamics of DNA structures in a bcl-2 promoter sequence is regulated by small molecules and the transcription factor hnRNP LL. Nucleic Acids Research, 2014, 42, 5755-5764.	6.5	33
22	The Dynamic Character of the BCL2 Promoter i-Motif Provides a Mechanism for Modulation of Gene Expression by Compounds That Bind Selectively to the Alternative DNA Hairpin Structure. Journal of the American Chemical Society, 2014, 136, 4161-4171.	6.6	218
23	The Transcriptional Complex Between the BCL2 i-Motif and hnRNP LL Is a Molecular Switch for Control of Gene Expression That Can Be Modulated by Small Molecules. Journal of the American Chemical Society, 2014, 136, 4172-4185.	6.6	207
24	Visualizing the quadruplex. Nature Chemistry, 2013, 5, 153-155.	6.6	20
25	Novel Targeting Of BCL2 and MYC DNA Secondary Structures In Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2013, 122, 2532-2532.	0.6	0
26	Tertiary DNA Structure in the Single-Stranded hTERT Promoter Fragment Unfolds and Refolds by Parallel Pathways via Cooperative or Sequential Events. Journal of the American Chemical Society, 2012, 134, 5157-5164.	6.6	71
27	The Major G-Quadruplex Formed in the Human Platelet-Derived Growth Factor Receptor Î² Promoter Adopts a Novel Broken-Strand Structure in K⁺ Solution. Journal of the American Chemical Society, 2012, 134, 13220-13223.	6.6	63
28	Anticancer Activity and Cellular Repression of c-MYC by the G-Quadruplex-Stabilizing 11-Piperazinylquindoline Is Not Dependent on Direct Targeting of the G-Quadruplex in the c-MYC Promoter. Journal of Medicinal Chemistry, 2012, 55, 6076-6086.	2.9	100
29	DNA acting like RNA. Biochemical Society Transactions, 2011, 39, 635-640.	1.6	10
30	Solution Structure of a 2:1 Quindolineâ€“c-MYC G-Quadruplex: Insights into G-Quadruplex-Interactive Small Molecule Drug Design. Journal of the American Chemical Society, 2011, 133, 17673-17680.	6.6	313
31	Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?. Nature Reviews Drug Discovery, 2011, 10, 261-275.	21.5	1,447
32	Demonstration that Drug-targeted Down-regulation of MYC in Non-Hodgkins Lymphoma Is Directly Mediated through the Promoter G-quadruplex. Journal of Biological Chemistry, 2011, 286, 41018-41027.	1.6	149
33	3-[4-(10H-Indolo[3,2-b]quinolin-11-yl)piperazin-1-yl]propan-1-ol. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o3465-o3466.	0.2	0
34	The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of GleevecÂ®, NexavarÂ®, and BIRB-796. Bioorganic and Medicinal Chemistry, 2010, 18, 5738-5748.	1.4	143
35	Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 292-304.	1.4	47
36	Making sense of Gâ€quadruplex and iâ€motif functions in oncogene promoters. FEBS Journal, 2010, 277, 3459-3469.	2.2	401

#	Article	IF	Citations
37	Targeting MYC Expression through G-Quadruplexes. Genes and Cancer, 2010, 1, 641-649.	0.6	250
38	Modulating the Functional Contributions of c-Myc to the Human Endothelial Cell Cyclic Strain Response. Journal of Vascular Research, 2010, 47, 80-90.	0.6	20
39	The role of G-quadruplex/i-motif secondary structures as cis-acting regulatory elements. Pure and Applied Chemistry, 2010, 82, 1609-1621.	0.9	64
40	Molecular Cloning of the Human Platelet-Derived Growth Factor Receptor Î² (PDGFR-Î²) Promoter and Drug Targeting of the G-Quadruplex-Forming Region To Repress PDGFR-Î² Expression. Biochemistry, 2010, 49, 4208-4219.	1.2	71
41	The c-MYCNHE III₁: Function and Regulation. Annual Review of Pharmacology and Toxicology, 2010, 50, 111-129.	4.2	154
42	Biochemical Techniques for the Characterization of G-Quadruplex Structures: EMSA, DMS Footprinting, and DNA Polymerase Stop Assay. Methods in Molecular Biology, 2010, 608, 65-79.	0.4	107
43	I-Motif Structures Formed in the Human c-MYC Promoter Are Highly Dynamicâ€“Insights into Sequence Redundancy and I-Motif Stability. PLoS ONE, 2010, 5, e11647.	1.1	68
44	Characterization of Novel Diaryl Oxazole-Based Compounds as Potential Agents to Treat Pancreatic Cancer. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 636-647.	1.3	49
45	UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Molecular Cancer Therapeutics, 2009, 8, 36-44.	1.9	48
46	NM23-H2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III1. Molecular Cancer Therapeutics, 2009, 8, 1363-1377.	1.9	97
47	Orally active Î±-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer. Molecular Cancer Therapeutics, 2009, 8, 1570-1578.	1.9	25
48	The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nature Reviews Cancer, 2009, 9, 849-861.	12.8	252
49	A Direct and Nondestructive Approach To Determine the Folding Structure of the I-Motif DNA Secondary Structure by NMR. Journal of the American Chemical Society, 2009, 131, 6102-6104.	6.6	39
50	Formation of a Unique End-to-End Stacked Pair of G-Quadruplexes in the hTERT Core Promoter with Implications for Inhibition of Telomerase by G-Quadruplex-Interactive Ligands. Journal of the American Chemical Society, 2009, 131, 10878-10891.	6.6	227
51	The i-Motif in the bcl-2 P1 Promoter Forms an Unexpectedly Stable Structure with a Unique 8:5:7 Loop Folding Pattern. Journal of the American Chemical Society, 2009, 131, 17667-17676.	6.6	125
52	The Importance of Negative Superhelicity in Inducing the Formation of G-Quadruplex and i-Motif Structures in the c-Myc Promoter: Implications for Drug Targeting and Control of Gene Expression. Journal of Medicinal Chemistry, 2009, 52, 2863-2874.	2.9	344
53	Identification and Characterization of Nucleolin as a c-myc G-quadruplex-binding Protein. Journal of Biological Chemistry, 2009, 284, 23622-23635.	1.6	267
54	Molecular modeling and biophysical analysis of the c-MYC NHE-III1 silencer element. Journal of Molecular Modeling, 2008, 14, 93-101.	0.8	33

#	Article	IF	Citations
55	Structures, folding patterns, and functions of intramolecular DNA G-quadruplexes found in eukaryotic promoter regions. Biochimie, 2008, 90, 1149-1171.	1.3	415
56	Intramolecularly folded G-quadruplex and i-motif structures in the proximal promoter of the vascular endothelial growth factor gene. Nucleic Acids Research, 2008, 36, 4598-4608.	6.5	156
57	Psorospermin structural requirements for P-glycoprotein resistance reversal. Molecular Cancer Therapeutics, 2008, 7, 3617-3623.	1.9	5
58	A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity. Nucleic Acids Research, 2008, 36, 1755-1769.	6.5	160
59	The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplexâ€“interactive agents. Molecular Cancer Therapeutics, 2008, 7, 880-889.	1.9	159
60	Identification of a novel inhibitor of urokinase-type plasminogen activator. Molecular Cancer Therapeutics, 2007, 6, 1348-1356.	1.9	46
61	Characterization of the G-quadruplexes in the duplex nuclease hypersensitive element of the PDGF-A promoter and modulation of PDGF-A promoter activity by TMPyP4. Nucleic Acids Research, 2007, 35, 7698-7713.	6.5	179
62	Formation of Pseudosymmetrical G-Quadruplex and i-Motif Structures in the Proximal Promoter Region of the RET Oncogene. Journal of the American Chemical Society, 2007, 129, 10220-10228.	6.6	235
63	Deconvoluting the Structural and Drug-Recognition Complexity of the G-Quadruplex-Forming Region Upstream of thebcl-2P1 Promoter. Journal of the American Chemical Society, 2006, 128, 5404-5415.	6.6	345
64	Drug Targeting of the c-MYC Promoter to Repress Gene Expression via a G-Quadruplex Silencer Element. Seminars in Oncology, 2006, 33, 498-512.	0.8	115
65	Dietary Administration of the Proapoptotic Vitamin E Analogue Î±-Tocopheryloxyacetic Acid Inhibits Metastatic Murine Breast Cancer. Cancer Research, 2006, 66, 9374-9378.	0.4	72
66	Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Molecular Cancer Therapeutics, 2006, 5, 1764-1773.	1.9	79
67	NMR solution structure of the major G-quadruplex structure formed in the human BCL2 promoter region. Nucleic Acids Research, 2006, 34, 5133-5144.	6.5	323
68	Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Molecular Cancer Therapeutics, 2006, 5, 2450-2458.	1.9	38
69	A Comprehensive Strategy to Combat Colon Cancer Targeting the Adenomatous Polyposis Coli Tumor Suppressor Gene. Annals of the New York Academy of Sciences, 2005, 1059, 97-105.	1.8	14
70	Determination of the importance of the stereochemistry of psorospermin in topoisomerase IIâ€“induced alkylation of DNA and in vitro and in vivo biological activity. Molecular Cancer Therapeutics, 2005, 4, 1729-1739.	1.9	20
71	Design and Synthesis of an Expanded Porphyrin That Has Selectivity for the c-MYC G-Quadruplex Structure. Journal of the American Chemical Society, 2005, 127, 2944-2959.	6.6	303
72	Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Research, 2005, 33, 6070-6080.	6.5	367

#	Article	IF	Citations
73	Evidence for the Presence of a Guanine Quadruplex Forming Region within a Polypurine Tract of the Hypoxia Inducible Factor 1Î± Promoterâ€. Biochemistry, 2005, 44, 16341-16350.	1.2	260
74	Conformationally Restricted Analogues of Psorospermin:Â Design, Synthesis, and Bioactivity of Natural-Product-Related Bisfuranoxanthones. Journal of Medicinal Chemistry, 2005, 48, 2993-3004.	2.9	35
75	Telomestatin and Diseleno Sapphyrin Bind Selectively to Two Different Forms of the Human Telomeric G-Quadruplex Structure. Journal of the American Chemical Society, 2005, 127, 9439-9447.	6.6	328
76	Telomerase Inhibition and Cell Growth Arrest After Telomestatin Treatment in Multiple Myeloma. Clinical Cancer Research, 2004, 10, 770-776.	3.2	110
77	Synthesis and Evaluation of a Triplex-Forming Oligonucleotideâ^'Pyrrolobenzodiazepine Conjugate. Bioconjugate Chemistry, 2004, 15, 1182-1192.	1.8	10
78	Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6140-6145.	3.3	52
79	The Dynamic Character of the G-Quadruplex Element in the c-MYC Promoter and Modification by TMPyP4. Journal of the American Chemical Society, 2004, 126, 8702-8709.	6.6	352
80	Design, Synthesis, and Evaluation of Psorospermin/Quinobenzoxazine Hybrids as Structurally Novel Antitumor Agents. Journal of Medicinal Chemistry, 2003, 46, 2958-2972.	2.9	35
81	Design, Synthesis, and Biological Evaluation of a Series of Fluoroquinoanthroxazines with Contrasting Dual Mechanisms of Action against Topoisomerase II and G-Quadruplexes. Journal of Medicinal Chemistry, 2003, 46, 571-583.	2.9	56
82	The cationic porphyrin TMPyP4 destabilizes the tetraplex form of the fragile X syndrome expanded sequence d(CGG)n. Nucleic Acids Research, 2003, 31, 3963-3970.	6.5	74
83	TELOMEREINHIBITION ANDTELOMEREDISRUPTION ASPROCESSES FORDRUGTARGETING. Annual Review of Pharmacology and Toxicology, 2003, 43, 359-379.	4.2	121
84	The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Research, 2003, 63, 3247-56.	0.4	165
85	Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Molecular Cancer Therapeutics, 2003, 2, 825-33.	1.9	70
86	Telomestatin, a Potent Telomerase Inhibitor That Interacts Quite Specifically with the Human Telomeric Intramolecular G-Quadruplex. Journal of the American Chemical Society, 2002, 124, 2098-2099.	6.6	494
87	Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11593-11598.	3.3	1,970
88	Telomeres and telomerases as drug targets. Current Opinion in Pharmacology, 2002, 2, 415-423.	1.7	137
89	DNA and its associated processes as targets for cancer therapy. Nature Reviews Cancer, 2002, 2, 188-200.	12.8	1,223
90	The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Molecular Cancer Therapeutics, 2002, 1, 565-73.	1.9	270

#	Article	IF	Citations
91	Quadruplex-Interactive Agents as Telomerase Inhibitors:Â Synthesis of Porphyrins and Structureâ^'Activity Relationship for the Inhibition of Telomerase. Journal of Medicinal Chemistry, 2001, 44, 4509-4523.	2.9	246
92	Selective Interactions of Cationic Porphyrins with G-Quadruplex Structures. Journal of the American Chemical Society, 2001, 123, 8902-8913.	6.6	311
93	Differential Rates of Reversibility of Ecteinascidin 743â^'DNA Covalent Adducts from Different Sequences Lead to Migration to Favored Bonding Sites. Journal of the American Chemical Society, 2001, 123, 6485-6495.	6.6	80
94	Targeting telomeres and telomerase. Methods in Enzymology, 2001, 340, 573-592.	0.4	14
95	Design and Synthesis of a Novel DNAâ^'DNA Interstrand Adenineâ^'Guanine Cross-Linking Agent. Journal of the American Chemical Society, 2001, 123, 4865-4866.	6.6	43
96	The inefficiency of incisions of ecteinascidin 743â€"DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chemistry and Biology, 2001, 8, 1033-1049.	6.2	69
97	Induction of Duplex to G-quadruplex Transition in the c-myc Promoter Region by a Small Molecule. Journal of Biological Chemistry, 2001, 276, 4640-4646.	1.6	184
98	DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs. Investigational New Drugs, 2000, 18, 123-137.	1.2	28
99	G-quadruplex DNA: a potential target for anti-cancer drug design. Trends in Pharmacological Sciences, 2000, 21, 136-142.	4.0	458
100	Telomere maintenance mechanisms as a target for drug development. Oncogene, 2000, 19, 6632-6641.	2.6	70
101	Cationic Porphyrins Promote the Formation of i-Motif DNA and Bind Peripherally by a Nonintercalative Mechanism. Biochemistry, 2000, 39, 15083-15090.	1.2	108
102	Structural Insight into a Quinolone-Topoisomerase II-DNA Complex. Journal of Biological Chemistry, 1999, 274, 17226-17235.	1.6	24
103	Interactions of TMPyP4 and TMPyP2 with Quadruplex DNA. Structural Basis for the Differential Effects on Telomerase Inhibition. Journal of the American Chemical Society, 1999, 121, 3561-3570.	6.6	327
104	Ecteinascidin 743:â€‰ A Minor Groove Alkylator That Bends DNA toward the Major Groove. Journal of Medicinal Chemistry, 1999, 42, 2493-2497.	2.9	203
105	31P-Nmr as a Probe for Drug-Nucleic Acid Interactions. Phosphorus, Sulfur and Silicon and the Related Elements, 1999, 144, 297-300.	0.8	0
106	A Thymine:Thymine Mismatch Enhances the Pluramycin Alkylation Site Downstream of the TBPâ^'TATA Box Complex. Journal of the American Chemical Society, 1999, 121, 8971-8977.	6.6	7
107	Mechanistic Insight into the Aromatization of Cyclic p-Quinonemethides to Indoles. Heterocycles, 1999, 51, 185.	0.4	1
108	Design of New Topoisomerase II Inhibitors Based upon a Quinobenzoxazine Self-Assembly Model. Journal of Medicinal Chemistry, 1998, 41, 4273-4278.	2.9	32

#	Article	IF	Citations
109	Cationic Porphyrins as Telomerase Inhibitors:Â the Interaction of Tetra-(N-methyl-4-pyridyl)porphine with Quadruplex DNA. Journal of the American Chemical Society, 1998, 120, 3261-3262.	6.6	415
110	Mechanism for the Catalytic Activation of Ecteinascidin 743 and Its Subsequent Alkylation of Guanine N2. Journal of the American Chemical Society, 1998, 120, 2490-2491.	6.6	66
111	Molecular Basis for the DNA Sequence Selectivity of Ecteinascidin 736 and 743:Â Evidence for the Dominant Role of Direct Readout via Hydrogen Bonding. Journal of the American Chemical Society, 1998, 120, 13028-13041.	6.6	66
112	NMR-Based Model of a Telomerase-Inhibiting Compound Bound to G-Quadruplex DNAâ€. Biochemistry, 1998, 37, 12367-12374.	1.2	369
113	Topoisomerase II Site-directed Alkylation of DNA by Psorospermin and Its Effect on Topoisomerase II-mediated DNA Cleavage. Journal of Biological Chemistry, 1998, 273, 33020-33026.	1.6	30
114	Telomerase Assay Using Biotinylated-Primer Extension and Magnetic Separation of the Products. BioTechniques, 1998, 25, 1046-1051.	0.8	40
115	NMR-Based Model of an Ecteinascidin 743â^'DNA Adduct. Journal of the American Chemical Society, 1997, 119, 5475-5476.	6.6	79
116	Replacement of the Bizelesin Ureadiyl Linkage by a Guanidinium Moiety Retards Translocation from Monoalkylation to Cross-Linking Sites on DNA. Journal of the American Chemical Society, 1997, 119, 3434-3442.	6.6	13
117	A New Class of Polyintercalating Molecules. Journal of the American Chemical Society, 1997, 119, 7202-7210.	6.6	106
118	Covalent Modification of N3 of Guanine by (+)-CC-1065 Results in Protonation of the Cross-Strand Cytosine. Journal of the American Chemical Society, 1997, 119, 629-630.	6.6	10
119	Inhibition of Human Telomerase by a G-Quadruplex-Interactive Compound. Journal of Medicinal Chemistry, 1997, 40, 2113-2116.	2.9	763
120	Pluramycins. Old Drugs Having Modern Friends in Structural Biology. Accounts of Chemical Research, 1996, 29, 249-258.	7.6	143
121	Manipulative Interplay of the Interstrand Cross-Linker Bizelesin with d(TAATTA)2To Achieve Sequence Recognition of DNA. Journal of the American Chemical Society, 1996, 118, 10052-10064.	6.6	8
122	Evidence for the Formation of 2:2 Drugâ^'Mg2+Dimers in Solution and for the Formation of Dimeric Drug Complexes on DNA from the DNA-Accelerated Photochemical Reaction of Antineoplastic Quinobenzoxazines. Journal of the American Chemical Society, 1996, 118, 7040-7048.	6.6	27
123	Cross-Linkage by â€œIntactâ€•Bizelesin and Bisalkylation by the â€œSeparated Halvesâ€•of the Bizelesin Dimer:Â Contrasting Drug Manipulation of DNA Conformation (5â€²-TAATTA-3â€²) Directs Alkylation toward Different Adenine Targets. Journal of the American Chemical Society, 1996, 118, 5383-5395.	6.6	10
124	Molecular Details of the Structure of a Psorosperminâ^'DNA Covalent/Intercalation Complex and Associated DNA Sequence Selectivity. Journal of the American Chemical Society, 1996, 118, 5553-5561.	6.6	47
125	The Chemical Evolution of DNAâ^'DNA Interstrand Cross-Linkers That Recognize Defined Mixed AT and GC Sequences. Journal of the American Chemical Society, 1996, 118, 10041-10051.	6.6	7
126	Thermally Induced DNAÂ·RNA Hybrid to G-Quadruplex Transitions:Â Possible Implications for Telomere Synthesis by Telomeraseâ€. Biochemistry, 1996, 35, 16110-16115.	1.2	69

#	Article	IF	Citations
127	Specific targeting of proteinâ€“DNA complexes by dna-reactive drugs (+)-CC-1065 and pluramycins. , 1996, 9, 75-87.		3
128	Synthesis of Sequence-Selective C8-Linked Pyrrolo[2,1-c][1,4]benzodiazepine DNA Interstrand Cross-Linking Agents. Journal of Organic Chemistry, 1996, 61, 8141-8147.	1.7	108
129	Molecular struggle for transcriptional control. Nature Medicine, 1995, 1, 525-527.	15.2	58
130	TBP binding to the TATA box induces a specific downstream unwinding site that is targeted by pluramycin. Chemistry and Biology, 1995, 2, 457-469.	6.2	24
131	Hedamycin intercalates the DNA helix and, through carbohydrate-mediated recognition in the minor groove, directs N7-alkylation of guanine in the major groove in a sequence-specific manner. Chemistry and Biology, 1995, 2, 229-240.	6.2	49
132	Comparison of a DSB-120 DNA interstrand crosslinked adduct with the corresponding bis-tomaymycin adduct: An example of a successful template-directed approach to drug design based upon the monoalkylating compound tomaymycin. [Erratum to document cited in CA121:195165]. Journal of Medicinal Chemistry, 1995, 38, 1052-1052.	2.9	0
133	Monoalkylation and Crosslinking of DNA by Cyclopropylpyrrolindoles Entraps Bent and Straight Forms of A-Tracts. Journal of the American Chemical Society, 1995, 117, 2371-2372.	6.6	16
134	Altromycin B Threads the DNA Helix Interacting with Both the Major and the Minor Grooves To Position Itself for Site-Directed Alkylation and Guanine N7. Journal of the American Chemical Society, 1995, 117, 2421-2429.	6.6	78
135	Molecular Basis for the DNA Sequence Specificity of the Pluramycins. A Novel Mechanism Involving Groove Interactions Transmitted through the Helix via Intercalation To Achieve Sequence Selectivity at the Covalent Bonding Step. Journal of the American Chemical Society, 1995, 117, 2430-2440.	6.6	56
136	Solution Conformation of a Bizelesin A-tract Duplex Adduct: DNAâ€“DNA Cross-linking of an A-tract Straightens Out Bent DNA. Journal of Molecular Biology, 1995, 252, 86-101.	2.0	27
137	Self-Assembly of a Quinobenzoxazine-Mg2+ Complex on DNA: A New Paradigm for the Structure of a Drug-DNA Complex and Implications for the Structure of the Quinolone Bacterial Gyrase-DNA Complex. Journal of Medicinal Chemistry, 1995, 38, 408-424.	2.9	104
138	(+)-CC-1065 as a probe for intrinsic and protein-induced bending of DNA. Journal of Molecular Recognition, 1994, 7, 123-132.	1.1	7
139	Binding of Sp1 to the 21-bp repeat region of SV40 DNA: effect of intrinsic and drug-induced DNA bending between GC boxes. Gene, 1994, 149, 165-172.	1.0	13
140	Structure of a Covalent DNA Minor Groove Adduct with a Pyrrolobenzodiazepine Dimer: Evidence for Sequence-Specific Interstrand Crosslinking. Journal of Medicinal Chemistry, 1994, 37, 4529-4537.	2.9	87
141	Comparison of a DSB-120 DNA Interstrand Cross-Linked Adduct with the Corresponding Bis-tomaymycin Adduct: An Example of a Successful Template-Directed Approach to Drug Design Based upon the Monoalkylating Compound Tomaymycin. Journal of Medicinal Chemistry, 1994, 37, 3132-3140.	2.9	47
142	Alkylation of guanine and cytosine in DNA by bizelesin. Evidence for a covalent immobilization leading to a proximity-driven alkylation of normally unreactive bases by a (+)-CC-1065 cross-linking compound. Chemical Research in Toxicology, 1993, 6, 889-894.	1.7	11
143	Synthesis and biochemical evaluation of the CBI-PDE-I-dimer, a benzannelated analog of (+)-CC-1065 that also produces delayed toxicity in mice. Journal of Medicinal Chemistry, 1993, 36, 1956-1963.	2.9	32
144	Analysis of the monoalkylation and cross-linking sequence specificity of bizelesin, a bifunctional alkylation agent related to (+)-CC-1065. Journal of the American Chemical Society, 1993, 115, 5925-5933.	6.6	33

#	Article	IF	Citations
145	(+)-CC-1065 as a structural probe of Mu transposase-induced bending of DNA: overcoming limitations of hydroxyl-radical footprinting. Nucleic Acids Research, 1993, 21, 4281-4287.	6.5	22
146	Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system. Journal of the American Chemical Society, 1992, 114, 4939-4941.	6.6	147
147	Template-directed design of a DNA-DNA crosslinker based upon a bis-tomaymycin-duplex adduct. Journal of Medicinal Chemistry, 1992, 35, 2995-3002.	2.9	41
148	Characterization of a 12-mer duplex d(GGCGGAGTTAGG).cntdot.d(CCTAACTCCGCC) containing a highly reactive (+)-CC-1065 sequence by proton and phosphorus-31 NMR, hydroxyl-radical footprinting, and NOESY restrained molecular dynamics calculations. Chemical Research in Toxicology, 1992, 5, 167-182.	1.7	30
149	Structure-activity relationships of (+)-CC-1065 analogs in the inhibition of helicase-catalyzed unwinding of duplex DNA. Journal of Medicinal Chemistry, 1992, 35, 1773-1782.	2.9	27
150	Determination of the structural features of (+)-CC-1065 that are responsible for bending and winding of DNA. Chemical Research in Toxicology, 1991, 4, 203-213.	1.7	51
151	(+)-CC-1065 produces bending of DNA that appears to resemble adenine/thymine tracts. Chemical Research in Toxicology, 1991, 4, 21-26.	1.7	38
152	Repair of helix-stabilizing anthramycin-N2 guanine DNA adducts by UVRA and UVRB proteins. Journal of Molecular Biology, 1991, 220, 855-866.	2.0	17
153	Sequence specificity of DNA alkylation by the unnatural enantiomer of CC-1065 and its synthetic analogs. Journal of the American Chemical Society, 1990, 112, 4633-4649.	6.6	117
154	Characterization of the structure of the anthramycin-d(ATGCAT)2 adduct by NMR and molecular modeling studies. Determination of the stereochemistry of the covalent linkage site, orientation in the minor groove of DNA, and effect on local DNA structure. Journal of the American Chemical Society, 1990, 112, 3279-3289.	6.6	30
155	DNA and associated targets for drug design. Journal of Medicinal Chemistry, 1989, 32, 2027-2033.	2.9	140
156	Sequence selectivity of DNA covalent modification. Chemical Research in Toxicology, 1988, 1, 315-333.	1.7	196
157	One- and two-dimensional proton NMR, fluorescence and molecular modeling studies on the tomaymycin-d(ATGCAT)2 adduct. Evidence for two covalent adducts with opposite orientations and stereochemistries at the covalent linkage site. Journal of Medicinal Chemistry, 1988, 31, 583-590.	2.9	34
158	Pyrrolo[1,4]benzodiazepine antitumor antibiotics: relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds. Chemical Research in Toxicology, 1988, 1, 258-268.	1.7	144
159	Reaction of CC-1065 and select synthetic analogs with DNA. Biochemical Pharmacology, 1988, 37, 1795-1796.	2.0	2
160	DNA as a target for drug action. Trends in Pharmacological Sciences, 1988, 9, 402-407.	4.0	68
161	Chapter 26 Approaches Toward the Design of Sequence-Specific Drugs for DNA. Annual Reports in Medicinal Chemistry, 1987, 22, 259-268.	0.5	15
162	Bio-organic and Natural Products Chemistry Molecular Biology Workshop. Pharmaceutical Research, 1987, 04, 439-442.	1.7	0

#	Article	IF	Citations
163	Covalent binding of antitumor antibiotics in the minor groove of DNA. Mechanism of action of CC-1065 and the pyrrolo(1,4)benzodiazepines. Accounts of Chemical Research, 1986, 19, 230-237.	7.6	132
164	The chemistry, mechanism of action and biological properties of CC-1065, a potent antitumor antibiotic.. Journal of Antibiotics, 1986, 39, 319-334.	1.0	119
165	Biosynthesis of the lincomycins. 1. Studies using stable isotopes on the biosynthesis of the propyl- and ethyl-L-hygric acid moieties of lincomycins A and B. Journal of the American Chemical Society, 1984, 106, 7873-7878.	6.6	51
166	Pyrrolo(l ,4)benzodiazepine Antitumor Antibiotics: Chemistry, Interaction with DNA, and Biological Implications. Pharmaceutical Research, 1984, 01, 52-59.	1.7	61
167	Limitations and factors affecting the lactam reduction approach to the synthesis of anthramycin analogs. Tetrahedron Letters, 1984, 25, 2649-2652.	0.7	19
168	Biosynthesis of the lincomycins. 2. Studies using stable isotopes on the biosynthesis of methylthiolincosaminide moiety of lincomycin A. Journal of the American Chemical Society, 1984, 106, 7878-7883.	6.6	43
169	Characterization of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex. Nucleic Acids Research, 1984, 12, 6159-6168.	6.5	32
170	Biosynthesis of the antitumor antibiotic CC-1065 by Streptomyces zelensis.. Journal of Antibiotics, 1983, 36, 383-390.	1.0	25
171	Chemical Conversion of Anthramycin 11-Methyl Ether to Didehydroanhydroanthramycin and Its Utilization in Studies of the Biosynthesis and Mechanism of Action of Anthramycin. Journal of Natural Products, 1981, 44, 38-44.	1.5	13
172	Sensitivity and permeability of the anthramycin producing organism Streptomyces refuineus to anthramycin and structurally related antibiotics.. Journal of Antibiotics, 1981, 34, 1171-1174.	1.0	5
173	Proof for the biosynthetic conversion of L-(indole-15N)tryptophan to (10-15N)anthramycin using (13C,15N) labelling in conjunction with 13C-NMR and mass spectral analysis.. Journal of Antibiotics, 1980, 33, 1167-1171.	1.0	8
174	Proposed structures of the pyrrolo(1,4)benzodiazepine antibiotic-deoxyribonucleic acid adducts. Biochemical Pharmacology, 1980, 29, 1307-1310.	2.0	10
175	Induction and potentiation of lethal and genetic effects of ultraviolet light by tobacco smoke condensates in yeast. Environmental Research, 1980, 21, 97-107.	3.7	7
176	Stereochemical aspects of the biosynthesis of spectinomycin. Journal of the American Chemical Society, 1980, 102, 6817-6820.	6.6	21
177	Elucidation and formulation of novel biosynthetic pathways leading to the pyrrolo[1,4]benzodiazepine antibiotics anthramycin, tomaymycin, and sibiromycin. Accounts of Chemical Research, 1980, 13, 263-269.	7.6	55
178	Proposed structure of the anthramycinâ€“DNA adduct. Nature, 1979, 282, 529-531.	13.7	124
179	Pathways of DNA repair operating in yeast treated with the pyrrolo(1,4)-benzodiazepine antitumor antibiotics.. Journal of Antibiotics, 1978, 31, 911-913.	1.0	8
180	Pyrrolo(1,4)benzodiazepine antitumor antibiotics. Comparative aspects of anthramycin, tomaymycin and sibiromycin.. Journal of Antibiotics, 1977, 30, 349-370.	1.0	173

#	Article	IF	Citations
181	Application of long-range spin-spin couplings in biosynthetic studies. Journal of Organic Chemistry, 1976, 41, 2932-2934.	1.7	13
182	Biosynthesis of anthramycin. Determination of the labeling pattern by the use of radioactive and stable isotope techniques. Journal of the American Chemical Society, 1975, 97, 4372-4378.	6.6	35
183	REGULATION OF ANTIBIOTIC PRODUCTION: CATABOLITE INHIBITION AND THE DUALISTIC EFFECT OF GLUCOSE ON INDOLMYCIN PRODUCTION. Journal of Antibiotics, 1974, 27, 49-56.	1.0	14